UA115333C2 - Склад есмололу для парентерального введення - Google Patents

Склад есмололу для парентерального введення

Info

Publication number
UA115333C2
UA115333C2 UAA201413014A UAA201413014A UA115333C2 UA 115333 C2 UA115333 C2 UA 115333C2 UA A201413014 A UAA201413014 A UA A201413014A UA A201413014 A UAA201413014 A UA A201413014A UA 115333 C2 UA115333 C2 UA 115333C2
Authority
UA
Ukraine
Prior art keywords
esmolol hydrochloride
solution
ready
pure
solvent
Prior art date
Application number
UAA201413014A
Other languages
English (en)
Ukrainian (uk)
Inventor
Рудольф Відманн
Original Assignee
ЕйОуПі ОРФАН ФАРМАСЬЮТІКАЛС АГ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48407551&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA115333(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ЕйОуПі ОРФАН ФАРМАСЬЮТІКАЛС АГ filed Critical ЕйОуПі ОРФАН ФАРМАСЬЮТІКАЛС АГ
Publication of UA115333C2 publication Critical patent/UA115333C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
UAA201413014A 2012-05-10 2013-05-08 Склад есмололу для парентерального введення UA115333C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12167443 2012-05-10
PCT/EP2013/059594 WO2013167657A1 (en) 2012-05-10 2013-05-08 Parenteral esmolol formulation

Publications (1)

Publication Number Publication Date
UA115333C2 true UA115333C2 (uk) 2017-10-25

Family

ID=48407551

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201413014A UA115333C2 (uk) 2012-05-10 2013-05-08 Склад есмололу для парентерального введення

Country Status (27)

Country Link
US (3) US20150087704A1 (enExample)
EP (1) EP2846776B1 (enExample)
JP (1) JP6220383B2 (enExample)
CN (1) CN104379134A (enExample)
AU (1) AU2013258031B2 (enExample)
BR (1) BR112014027870B1 (enExample)
CA (1) CA2872953C (enExample)
CL (1) CL2014003028A1 (enExample)
DK (1) DK2846776T3 (enExample)
EA (1) EA032344B1 (enExample)
ES (1) ES2794093T3 (enExample)
HR (1) HRP20200897T1 (enExample)
HU (1) HUE049314T2 (enExample)
IL (1) IL235497A0 (enExample)
LT (1) LT2846776T (enExample)
MA (1) MA37500B1 (enExample)
MX (1) MX374771B (enExample)
MY (1) MY173900A (enExample)
NZ (1) NZ701429A (enExample)
PH (1) PH12014502494B1 (enExample)
PL (1) PL2846776T3 (enExample)
PT (1) PT2846776T (enExample)
SI (1) SI2846776T1 (enExample)
TN (1) TN2014000464A1 (enExample)
UA (1) UA115333C2 (enExample)
WO (1) WO2013167657A1 (enExample)
ZA (1) ZA201408149B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019122157A1 (en) * 2017-12-21 2019-06-27 Ipsol Ag A lyophilisate comprising esmolol and adenosine for use in cardioplegia
CN111848420A (zh) * 2020-07-22 2020-10-30 杭州煌森生物科技有限公司 一种盐酸艾司洛尔的新晶型及制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6310094B1 (en) * 2001-01-12 2001-10-30 Baxter International Inc. Ready-to-use esmolol solution
TWI277414B (en) 2001-01-12 2007-04-01 Baxter Int Esmolol formulation
SE0401842D0 (sv) * 2004-07-12 2004-07-12 Dizlin Medical Design Ab Infusion and injection solution of levodopa
KR20080039954A (ko) * 2005-08-31 2008-05-07 오노 야꾸힝 고교 가부시키가이샤 점적용 주사제
US20080293814A1 (en) * 2007-05-22 2008-11-27 Deepak Tiwari Concentrate esmolol
ES2397126T3 (es) 2007-12-21 2013-03-04 Aop Orphan Pharmaceuticals Ag Composición farmacéutica para la administración parenteral de un antagonista del receptor beta-adrenérgico de acción ultrarrápida
CN102106846A (zh) * 2009-12-23 2011-06-29 南京海辰药业有限公司 左旋盐酸艾司洛尔药物组合物及其制备方法

Also Published As

Publication number Publication date
CA2872953A1 (en) 2013-11-14
EA032344B1 (ru) 2019-05-31
EP2846776A1 (en) 2015-03-18
US20220249424A1 (en) 2022-08-11
EP2846776B1 (en) 2020-04-15
ES2794093T3 (es) 2020-11-17
TN2014000464A1 (en) 2016-03-30
BR112014027870A2 (pt) 2017-06-27
PH12014502494A1 (en) 2015-01-12
JP2015520142A (ja) 2015-07-16
MA37500B1 (fr) 2016-12-30
HUE049314T2 (hu) 2020-09-28
NZ701429A (en) 2016-04-29
BR112014027870B1 (pt) 2023-04-25
US20150087704A1 (en) 2015-03-26
PL2846776T3 (pl) 2020-09-21
US11963940B2 (en) 2024-04-23
SI2846776T1 (sl) 2020-08-31
HK1204265A1 (en) 2015-11-13
ZA201408149B (en) 2016-08-31
MX2014013556A (es) 2015-01-16
AU2013258031A1 (en) 2014-11-20
CA2872953C (en) 2020-04-07
DK2846776T3 (da) 2020-06-15
PT2846776T (pt) 2020-05-28
EA201491841A1 (ru) 2015-02-27
WO2013167657A1 (en) 2013-11-14
CN104379134A (zh) 2015-02-25
LT2846776T (lt) 2020-06-25
BR112014027870A8 (pt) 2023-01-17
US20170326095A1 (en) 2017-11-16
AU2013258031B2 (en) 2017-08-03
MY173900A (en) 2020-02-26
CL2014003028A1 (es) 2015-06-19
JP6220383B2 (ja) 2017-10-25
PH12014502494B1 (en) 2019-11-13
IL235497A0 (en) 2014-12-31
MA37500A1 (fr) 2016-03-31
HRP20200897T1 (hr) 2020-11-27
MX374771B (es) 2025-03-06

Similar Documents

Publication Publication Date Title
HRP20200072T1 (hr) Načini doziranja za spojeve klase ehinokandina
MX389346B (es) Formulaciones de anticuerpos monoclonales de alta concentración.
EA201492021A1 (ru) Антительный состав
IN2014DN08598A (enExample)
RU2015116264A (ru) Композиции и способы лечения сердечной недостаточности у пациентов с диабетом
EA201691055A1 (ru) Препараты и способы лечения gd2-положительного рака
MX348418B (es) Composicion ocular que contiene bromfenaco con biodisponibilidad incrementada.
PH12014502494A1 (en) Parenteral esmolol formulation
PE20130782A1 (es) Composiciones farmaceuticas que consisten de paracetamol y el proceso para la preparacion del mismo
WO2014165829A3 (en) Nanoparticle formulations
EA201500128A1 (ru) Педиатрические жидкие композиции для перорального введения, содержащие непадутант
JO3689B1 (ar) صيغ من الباراسيتامول قابلة للحقن
RU2013142835A (ru) Способ лечения ишемического инсульта
UA69674U (ru) Способ лечения больных на эритематозно-бульозной рожей
TH155633A (th) สูตรผสมแบบฉีดของเอสโมลอล
UA64881U (ru) Способ лечения печеночной недостаточности пострадавших с травмой печени
AR085988A1 (es) Tratamientos de la infeccion del virus de la hepatitis c
UA79052U (ru) Способ иммунокоррекции при обострениях хронического бронхита у больных с инсулинорезистентностью
UA72334U (uk) Фармацевтичний склад для приготування розчину для парентерального введення людині
UA89638U (ru) Способ лечения больных пожилого возраста с синдромом сосудистых умеренных когнитивных нарушений
GR1008260B (el) Ενδοφλεβιο σκευασμα λινεζολιδης και μεθοδος για την παρασκευη αυτου
RU2012110137A (ru) Способ лечения инсулинорезистентности
UA69682U (ru) Способ профилактики обострений вирусного гепатита А у взрослых больных
RU2012154460A (ru) Способ профилактики технологического стресса у ягнят при отъеме
UA69978U (ru) Способ лечения больных первичной рожей